Ascletis Pharma Reports ASC36 Achieves Superior Weight Loss in Preclinical Obesity Studies

Reuters

Oct 30

Ascletis Pharma Reports ASC36 Achieves Superior Weight Loss in Preclinical Obesity Studies

Ascletis Pharma Inc. has announced the selection of ASC36, a once-monthly subcutaneously administered amylin receptor agonist, as a clinical development candidate for the treatment of obesity. In preclinical studies, ASC36 showed an average observed half-life of approximately 15 days in non-human primates, which is three times longer than petrelintide, supporting its potential for once-monthly dosing in humans. Additionally, ASC36 demonstrated approximately 91% greater relative body weight reduction compared to petrelintide in a diet-induced obese rat study. The company expects to submit an Investigational New Drug Application (IND) for ASC36 to the U.S. FDA in the second quarter of 2026. These results and further plans for monotherapy and combination therapies with ASC36 were announced but have not yet been presented at a scientific conference.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ascletis Pharma Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: CN09981) on October 30, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2579315619"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2579315619\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2579315619?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-30 08:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2579315619","market":"us","top_or_hot":-1,"title":"Ascletis Pharma Reports ASC36 Achieves Superior Weight Loss in Preclinical Obesity Studies","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Ascletis Pharma Reports ASC36 Achieves Superior Weight Loss in Preclinical Obesity Studies\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/ASCLF\">Ascletis Pharma Inc.</a> has announced the selection of ASC36, a once-monthly subcutaneously administered amylin receptor agonist, as a clinical development candidate for the treatment of obesity. In preclinical studies, ASC36 showed an average observed half-life of approximately 15 days in non-human primates, which is three times longer than petrelintide, supporting its potential for once-monthly dosing in humans. Additionally, ASC36 demonstrated approximately 91% greater relative body weight reduction compared to petrelintide in a diet-induced obese rat study. The company expects to submit an Investigational New Drug Application (IND) for ASC36 to the U.S. FDA in the second quarter of 2026. These results and further plans for monotherapy and combination therapies with ASC36 were announced but have not yet been presented at a scientific conference.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ascletis Pharma Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: CN09981) on October 30, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ascletis Pharma Reports ASC36 Achieves Superior Weight Loss in Preclinical Obesity Studies</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAscletis Pharma Reports ASC36 Achieves Superior Weight Loss in Preclinical Obesity Studies\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-10-30 08:10</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Ascletis Pharma Reports ASC36 Achieves Superior Weight Loss in Preclinical Obesity Studies\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/ASCLF\">Ascletis Pharma Inc.</a> has announced the selection of ASC36, a once-monthly subcutaneously administered amylin receptor agonist, as a clinical development candidate for the treatment of obesity. In preclinical studies, ASC36 showed an average observed half-life of approximately 15 days in non-human primates, which is three times longer than petrelintide, supporting its potential for once-monthly dosing in humans. Additionally, ASC36 demonstrated approximately 91% greater relative body weight reduction compared to petrelintide in a diet-induced obese rat study. The company expects to submit an Investigational New Drug Application (IND) for ASC36 to the U.S. FDA in the second quarter of 2026. These results and further plans for monotherapy and combination therapies with ASC36 were announced but have not yet been presented at a scientific conference.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ascletis Pharma Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: CN09981) on October 30, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251030:nNDLch5r9m:1","article_id":"2579315619","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2579315619","pubTimestamp":1761783024,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Ascletis Pharma Inc. has announced the selection of ASC36, a once-monthly subcutaneously administered amylin receptor agonist, as a clinical development candidate for the treatment of obesity. In preclinical studies, ASC36 showed an average observed half-life of approximately 15 days in non-human primates, which is three times longer than petrelintide, supporting its potential for once-monthly dosing in humans. Additionally, ASC36 demonstrated approximately 91% greater relative body weight reduction compared to petrelintide in a diet-induced obese rat study. The company expects to submit an Investigational New Drug Application  for ASC36 to the U.S. FDA in the second quarter of 2026. These results and further plans for monotherapy and combination therapies with ASC36 were announced but have not yet been presented at a scientific conference.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1161":"生物科技","BK1574":"生物医药B类股","BK1515":"抗疫概念","01672":"歌礼制药-B"},"translate_title":"歌礼制药报告ASC36在临床前肥胖研究中实现卓越的减肥效果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01672":0.9},"content_text":"Ascletis Pharma Reports ASC36 Achieves Superior Weight Loss in Preclinical Obesity Studies\n    \n\nAscletis Pharma Inc. has announced the selection of ASC36, a once-monthly subcutaneously administered amylin receptor agonist, as a clinical development candidate for the treatment of obesity. In preclinical studies, ASC36 showed an average observed half-life of approximately 15 days in non-human primates, which is three times longer than petrelintide, supporting its potential for once-monthly dosing in humans. Additionally, ASC36 demonstrated approximately 91% greater relative body weight reduction compared to petrelintide in a diet-induced obese rat study. The company expects to submit an Investigational New Drug Application (IND) for ASC36 to the U.S. FDA in the second quarter of 2026. These results and further plans for monotherapy and combination therapies with ASC36 were announced but have not yet been presented at a scientific conference.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ascletis Pharma Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: CN09981) on October 30, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport,express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}